Skip to main content

Table 3 Results of cost-effectiveness analysis

From: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Group E (QALY) IE (QALY) C (JPY 1000) IC (JPY 1000)
S-1 2.11 0.070 5307
[USD 47,000]
[USD 3750]
Taxane 2.04   5731
[USD 50,700]
  1. E Effectiveness, IE Incremental effectiveness, C Cost, IC Incremental cost